AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Clinical trials for AMYOTROPHIC LATERAL SCLEROSIS (ALS) explained in plain language.
Never miss a new study
Get alerted when new AMYOTROPHIC LATERAL SCLEROSIS (ALS) trials appear
Sign up with your email to follow new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental ALS drug RJK002 enters first human safety trial
Disease control OngoingThis early-stage study tests whether a single injection of RJK002 into the spinal fluid is safe for people with ALS, a progressive nerve disease. Nine adults with ALS will receive the drug and be monitored for side effects and changes in daily function. The goal is to find a safe…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE1 • Sponsor: RJK Biopharma Ltd • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
New ALS drug usnoflast faces crucial test in 240 patients
Disease control OngoingThis study tests whether the drug usnoflast can slow the progression of ALS, a serious nerve disease that weakens muscles over time. About 240 adults with ALS will receive either usnoflast or a placebo for 36 weeks. Researchers will measure changes in daily function and survival …
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated May 04, 2026 16:30 UTC
-
New hope for ALS: experimental drug VHB937 enters phase 2 trial
Disease control OngoingThis study tests whether VHB937 can slow down the progression of ALS, a disease that weakens muscles over time. About 251 people with early-stage ALS (symptoms for less than 2 years) will receive either VHB937 or a placebo for 40 weeks, followed by an open-label extension where e…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 04, 2026 16:20 UTC
-
New hope for ALS: NUZ-001 drug enters major trial
Disease control ENROLLING_BY_INVITATIONThis study tests a drug called NUZ-001 in 160 people with ALS, a disease that weakens muscles over time. The goal is to see if the drug can slow the disease and help people live longer. Participants take the drug and are monitored for changes in movement, breathing, and survival.
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE2, PHASE3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
Robotic glove gives ALS patients a helping hand
Symptom relief ENROLLING_BY_INVITATIONThis small pilot study tests whether using a robotic glove for 20 minutes a day, 5 days a week, can improve grip strength, fine motor skills, and quality of life in people with ALS. Five participants with a caregiver will use the glove at home for 8 weeks. The goal is to see if t…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: NA • Sponsor: Nova Southeastern University • Aim: Symptom relief
Last updated May 14, 2026 12:06 UTC
-
Brain mapping study aims to predict how neurodegenerative diseases spread
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how diseases like frontotemporal dementia and ALS spread through the brain's network, called the connectome. Researchers will use MRI scans and other tests to track changes over two years in 645 people, including patients and healthy volunteers. The goal is to…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: NA • Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC